The differential effects of wild-type and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics

Molecular and Cellular Biology

Volumn 33, Issue 9, 2013, Pages 1859-1868

  Romano, David ^a   Maccario, Helene ^a   Doherty, Carolanne ^a   Quinn, Niall P ^a   Kolch, Walter ^a   Matallanas, David ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; K RAS PROTEIN; LATS1 PROTEIN; MST2 PROTEIN; PEPTIDE; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WILD TYPE;

APOPTOSIS; CELL LINE, TUMOR; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; GENES, RAS; HELA CELLS; HUMANS; MUTATION; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84876432917     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01414-12     Document Type: Article

References (44)

1. Barbacid M. 1987. ras genes. Annu. Rev. Biochem. 56:779-827.
2. Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3:11-22.
3. Buday L, Downward J. 2008. Many faces of Ras activation. Biochim. Biophys. Acta 1786:178-187.
4. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Basecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA. 2011. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135-164.
5. Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7:295-308.
6. Aksamitiene E, Kiyatkin A, Kholodenko BN. 2012. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem. Soc. Trans. 40:139-146.
7. Matallanas D, Romano D, Al-Mulla F, O'Neill E, Al-Ali W, Crespo P, Doyle B, Nixon C, Sansom O, Drosten M, Barbacid M, Kolch W. 2011. Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol. Cell 44:893-906.
8. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J. 2002. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 21:1381-1390.
9. Agathanggelou A, Cooper WN, Latif F. 2005. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 65:3497-3508.
10. Donninger H, Vos MD, Clark GJ. 2007. The RASSF1A tumor suppressor. J. Cell Sci. 120:3163-3172.
11. Yee KS, Grochola L, Hamilton G, Grawenda A, Bond EE, Taubert H, Wurl P, Bond GL, O'Neill E. 2012. A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res. 72:2206-2217.
12. Baksh S, Tommasi S, Fenton S, Yu VC, Martins LM, Pfeifer GP, Latif F, Downward J, Neel BG. 2005. The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol. Cell 18:637-650.
13. Vos MD, Dallol A, Eckfeld K, Allen NP, Donninger H, Hesson LB, Calvisi D, Latif F, Clark GJ. 2006. The RASSF1A tumor suppressor activates Bax via MOAP-1. J. Biol. Chem. 281:4557-4563.
14. Avruch J, Praskova M, Ortiz-Vega S, Liu M, Zhang XF. 2006. Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods Enzymol. 407:290-310.
15. Guo C, Tommasi S, Liu L, Yee JK, Dammann R, Pfeifer GP. 2007. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr. Biol. 17:700-705.
16. Matallanas D, Romano D, Hamilton G, Kolch W, O'Neill E. 2008. A Hippo in the ointment: MST signalling beyond the fly. Cell Cycle 7:879-884.
17. Mauviel A, Nallet-Staub F, Varelas X. 2012. Integrating developmental signals: a Hippo in the (path)way. Oncogene 31:1743-1756.
18. Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D, Baccarini M, Vass JK, Kolch W, O'Neill E. 2007. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol. Cell 27:962-975.
19. O'Neill E, Rushworth L, Baccarini M, Kolch W. 2004. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306:2267-2270.
20. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. 2010. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF- (beta-TRCP). Genes Dev. 24:72-85.
21. Pan D. 2010. The hippo signaling pathway in development and cancer. Dev. Cell 19:491-505.
22. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, Blandino G. 2005. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol. Cell 18: 447-459.
23. Arozarena I, Aaronson DS, Matallanas D, Sanz V, Ajenjo N, Tenbaum SP, Teramoto H, Ighishi T, Zabala JC, Gutkind JS, Crespo P. 2000. The Rho family GTPase Cdc42 regulates the activation of Ras/MAP kinase by the exchange factor Ras-GRF. J. Biol. Chem. 275:26441-26448.
24. Arozarena I, Matallanas D, Berciano MT, Sanz-Moreno V, Calvo F, Munoz MT, Egea G, Lafarga M, Crespo P. 2004. Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors. Mol. Cell. Biol. 24:1516-1530.
25. Matallanas D, Arozarena I, Berciano MT, Aaronson DS, Pellicer A, Lafarga M, Crespo P. 2003. Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J. Biol. Chem. 278:4572-4581.
26. Feig LA, Buchsbaum RJ. 2002. Cell signaling: life or death decisions of ras proteins. Curr. Biol. 12:R259-261.
27. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, Seed B, Avruch J. 2002. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12:253-265.
28. Rodriguez-Viciana P, Sabatier C, McCormick F. 2004. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24:4943-4954.
29. Stieglitz B, Bee C, Schwarz D, Yildiz O, Moshnikova A, Khokhlatchev A, Herrmann C. 2008. Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J. 27:1995-2005.
30. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. 2000. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 275:35669-35672.
31. Creasy CL, Chernoff J. 1995. Cloning and characterization of a member of the MST subfamily of Ste20-like kinases. Gene 167:303-306.
32. Vavvas D, Li X, Avruch J, Zhang XF. 1998. Identification of Nore1 as a potential Ras effector. J. Biol. Chem. 273:5439-5442.
33. Romano D, Matallanas D, Weitsman G, Preisinger C, Ng T, Kolch W. 2010. Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res. 70:1195-1203.
34. Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J. 2004. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem. J. 381:453-462.
35. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. 1993. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85-88.
36. Cox AD, Der CJ. 2003. The dark side of Ras: regulation of apoptosis. Oncogene 22:8999-9006.
37. Castellano E, Santos E. 2011. Functional specificity of ras isoforms: so similar but so different. Genes Cancer 2:216-231.
38. Hamilton M, Wolfman A. 1998. Oncogenic Ha-Ras-dependent mitogenactivated protein kinase activity requires signaling through the epidermal growth factor receptor. J. Biol. Chem. 273:28155-28162.
39. Fotiadou PP, Takahashi C, Rajabi HN, Ewen ME. 2007. Wild-type NRas and KRas perform distinct functions during transformation. Mol. Cell. Biol. 27:6742-6755.
40. Liao J, Planchon SM, Wolfman JC, Wolfman A. 2006. Growth factordependentAKTactivation and cell migration requires the function of c-K(B)- Ras versus other cellular ras isoforms. J. Biol. Chem. 281:29730-29738.
41. Jeng HH, Taylor LJ, Bar-Sagi D. 2012. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat. Commun. 3:1168.
42. Young A, Lou D, McCormick F. 2013. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3:112-123.
43. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. 2003. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol. 21:3226-3235.
44. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C. 1992. p53 and RAS gene mutations in multiple myeloma. Oncogene 7:2539-2543.